Aratana Therapeutics (PETX) Files $57.5M IPO
Tweet
Share
E-mailGet Alerts PETX Hot Sheet
Join SI Premium – FREE
Aratana Therapeutics (NASDAQ: PETX) filed a $57.5 million IPO on form S-1 with the SEC. The company plans to list on the The NASDAQ Global Market under the symbol "PETX."
Stifel and Lazard Capital Markets are leading the offering with help from William Blair, JMP Securities and Craig-Hallum Capital Group.
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. Since its founding in 2010, the company has licensed three compounds, AT-001, AT-002 and AT-003 that and are developing into six products for use in pets in the United States and Europe.
Stifel and Lazard Capital Markets are leading the offering with help from William Blair, JMP Securities and Craig-Hallum Capital Group.
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics. Since its founding in 2010, the company has licensed three compounds, AT-001, AT-002 and AT-003 that and are developing into six products for use in pets in the United States and Europe.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Group 1 Automotive (GPI) Sells Brazil Operations for BRL 510M
- LogicMark (LGMK) Issues Letter to Shareholders
- Cuentas, Inc. (CUEN) Files $75M Mixed Shelf
Create E-mail Alert Related Categories
IPOsRelated Entities
William Blair, Lazard, JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
